Apoptosis Regulators in Cancer

Apoptosis is a regulated cell-death programme that can prevent damaged or oncogene-stressed cells from persisting. The intrinsic mitochondrial pathway is governed by interactions among anti-apoptotic BCL2-family proteins (including BCL2, MCL1 and BCL-XL), BH3-only sensors, and the pore-forming proteins BAX and BAK. Tumours can shift this balance toward survival through several mechanisms, sometimes creating a measurable dependency on a particular anti-apoptotic protein rather than one universal vulnerability.

Quick Answer

Genes that determine whether a damaged or stressed cell lives or dies. Cancer hijacks these to evade programmed cell death. This category links the major genes to their molecular mechanisms, cancer associations, and related pathway pages.

Key Genes in This Category

BCL2

Anti-apoptotic BCL2-family protein that restrains mitochondrial outer-membrane permeabilisation. Venetoclax directly inhibits BCL2; the current FDA label covers defined CLL/SLL populations and combination treatment in a defined newly diagnosed AML population, not multiple myeloma.

TP53

Activates pro-apoptotic BAX, PUMA, and NOXA in response to irreparable DNA damage, shifting the BCL2-family balance toward mitochondrial permeabilisation and caspase cascade initiation. p53 is lost in >50% of cancers partly because it drives apoptosis so effectively.

AKT1

Serine/threonine kinase that blocks apoptosis by phosphorylating BAD (preventing BCL2 dissociation), inactivating FOXO3a (a pro-apoptotic transcription factor), and activating MDM2 to degrade p53. Central pro-survival hub in the PI3K pathway.

PTEN

Opposes PI3K/AKT survival signalling; its loss releases constitutive AKT-driven anti-apoptotic activity. PTEN loss-of-function is one of the most direct routes to apoptosis resistance, affecting ~30% of glioblastomas and prostate cancers.

MCL1

Short-lived anti-apoptotic BCL2-family member frequently amplified in haematological malignancies and solid tumours. Its rapid turnover (half-life ~30 minutes) makes cancer cells dependent on continuous translation; MCL1 inhibitors are in clinical development.

HIF1A

Under hypoxia, transcriptionally upregulates anti-apoptotic BCL2 and MCL1 while downregulating cytochrome c release, enabling tumour cells to survive the low-oxygen microenvironment. HIF-1α simultaneously drives VEGFA for angiogenic rescue.

STAT3

Constitutively active STAT3 drives BCL-XL, MCL1, and survivin expression in tumour cells, creating an anti-apoptotic programme downstream of JAK activation. Its combination of proliferative and survival outputs makes STAT3 a particularly potent oncogene.

MYC

Paradoxically sensitises cells to apoptosis as a tumour-suppressive safeguard. This oncogene-induced apoptosis requires co-mutations — typically BCL2 amplification, p53 loss, or MCL1 overexpression — for cancer cells overexpressing MYC to survive.

MTOR

mTORC2 phosphorylates and fully activates AKT at Ser473, contributing to survival signalling. Rapamycin/everolimus blocks mTORC1 but can paradoxically activate AKT through IRS-1 feedback relief; dual PI3K/mTOR inhibitors aim to suppress both arms.

VEGFA

Beyond angiogenesis, VEGFA promotes tumour cell survival through autocrine VEGFR1/2 signalling that activates PI3K/AKT in cancer cells directly. Anti-VEGF therapies may therefore have both anti-angiogenic and pro-apoptotic effects.

Pathways and evidence guides

Move from the gene list into a mechanism map or a focused interpretation guide.

Apoptosis pathway

Follow mitochondrial permeabilisation and caspase activation.

BCL2 family and cancer survival

Compare pro- and anti-apoptotic family members.

TP53 mutations

See how p53 connects damage sensing to arrest or death.

BCL2 gene profile

Review gene function, partners and evidence sources.

Core sources

Authoritative overviews and peer-reviewed sources supporting this category summary.

1The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death & Differentiation, 2018. Source
2BCL-2 family proteins: changing partners in the dance towards death. Cell Death & Differentiation, 2018. Source
3VENCLEXTA prescribing information. U.S. Food and Drug Administration, 2026. Source

Explore Other Categories

Tumor Suppressor Genes

Proteins that act as molecular brakes on cell division. Loss of both copies unlocks uncontrolled proliferation.

Oncogenes

Gain-of-function mutations in growth-promoting genes that drive continuous cell division, even without normal growth signals.

DNA Repair Genes

Genes maintaining genome integrity through detection and correction of DNA damage. Their loss drives mutagenesis and cancer predisposition.

Cell Cycle Regulators

Proteins controlling when and how cells divide. Disruption of these checkpoints is nearly universal in human cancer.